BioNexus Gene Lab 株価情報 (NASDAQ: BGLC)

最新ニュース BioNexus Gene Lab (NASDAQ:BGLC) 株価情報

BioNexus Gene Lab

BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.

BioNexus Gene Lab Corp

JP Morgan analyst Anupam Rama issued a note on Thursday maintaining a positive outlook on Kiniksa Pharmaceuticals International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KNSA#NASDAQ">KNSA</a>), citing Arcalyst&#8217;s strong commercial performance and the<a href="https://www.benzinga.com/general/biotech"> company's focused pipeline. </a>
JP Morgan maintains the Overweight rating with a <a href="https://www.benzinga.com/quote/KNSA/analyst-ratings" target="_blank" rel="noreferrer noopener">price target of $40</a>.
Rama values Kiniksa shares in the low-$30s on Arcalyst alone and estimates a range in the high-$30s to low-$40s when including probability-adjusted KPL-387. The analyst believes the strategic focus on recurrent pericarditis (RP) provides clear opportunities for growth.
&#8220;As a result, we think KNSA shares are attractive from a valuation perspective, driven by both the commercial prospects of Arcalyst as well as the undervalued pipeline,&#8221; the analyst adds.
In February, Kiniksa Pharmaceuticals released a development update that said it would focus on cardiovascular indications.
<ul>
<li>The company discontinued abiprubart development in Sjögren&#8217;s Disease. The company will explore strategic alternatives for the asset.</li>
<li>Kiniksa also announced that it has exercised its right to terminate its exclusive license agreement for mavrilimumab with AstraZeneca Plc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) MedImmune.</li>
</ul>
Kiniksa is developing KPL-387 for recurrent pericarditis (RP) with a target profile of monthly <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43937097/kiniksa-pharmaceuticals-announces-development-of-kpl-387-in-recurrent-pericarditis-and-updates-cor" rel="noreferrer noopener">subcutaneous (SC) dosing</a>.
<ul>
<li>Recurrent pericarditis is&nbsp;a condition where the pericardium becomes inflamed again after a period of symptom-free time.&nbsp;The pericardium is a sac that surrounds the heart.&nbsp;</li>
<li>Kiniksa is conducting a single ascending dose (SAD) and multiple ascending dose Phase 1 trial of KPL-387 in healthy volunteers.</li>
<li>Kiniksa has interacted with the U.S. Food and Drug Administration (FDA) and expects to initiate a Phase 2/3 trial of KPL-387 in recurrent pericarditis in mid-2025. Phase 2 data are expected in the second half of 2026.</li>
</ul>
Arcalyst net product revenue was $122.5 million and $417.0 million for the fourth quarter and full year 2024, respectively. The company expects 2025 Arcalyst revenues of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43937111/kiniksa-pharmaceuticals-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-por" rel="noreferrer noopener">$560 million-$580 million</a>.
Price Action: KNSA stock is down 1.6% at $21.04 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/03/44165513/taiwan-semiconductor-ceo-taiwan-president-to-discuss-100-billion-us-expansion-not-afraid-of-losing-us-subsidies" target="_blank" rel="noreferrer noopener">Taiwan Semiconductor CEO, Taiwan President To Discuss $100 Billion US Expansion, &#8216;Not Afraid&#8217; Of Losing US Subsidies</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Biotech

News

Health Care

Analyst Ratings

General

KNSA

Kiniksa Pharmaceuticals Stock Is Attractive From Valuation Perspective-JP Morgan Analyst

<img alt="Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico. High quality photo — Photo" class="article-image-one" src="https://www.marketbeat.com/logos/articles/med_20250304152646_tariffs-wont-stop-these-3-stocks-from-rising.jpg" style="height:800px; width:1200px" />
As if investors didn&#39;t have enough to worry about, the Trump tariffs have gone into effect. As other nations begin to retaliate, this could be the initial battle in a prolonged trade war. Stocks are sinking across the board consequently, and that includes some of the top names from 2024, which don&#39;t look as magnificent in 2025.
Tariffs put pressure on corporate earnings and consumer spending, which is leading to cries of recession. However, what makes this particular tariff program so unsettling is its seemingly random, unpredictable nature. Are the tariffs being used to drive down interest rates? Are they being used to drive onshore manufacturing? Or are they, as President Trump says, about leverage to achieve policy objectives?
It makes for an uncertain time, and markets hate uncertainty.
It&#39;s only natural to be concerned, but this isn&#39;t the time to panic. Having discipline and a diversified outlook can help you find stocks that are likely to move higher even as the effects of tariffs start to take effect. Here are three names to consider.
<h2>Fortinet: A Defensive Play on the AI Trade</h2>
Cybersecurity stocks are one area for investors to look for stocks that are likely to grow in an uncertain tariff environment. <a href="https://www.marketbeat.com/stocks/NASDAQ/FTNT/" rel="noreferrer noopener" target="_blank">Fortinet Inc. (NASDAQ: </a><a class="ticker" href="https://www.benzinga.com/stock/ftnt#NASDAQ">FTNT</a>) is one of the top names to consider. The company is primarily focused on the hardware firewall niche through a unified platform.
[content-module:CompanyOverview|NASDAQ:FTNT]
Analysts are forecasting a significant upgrade cycle in 2026 and 2027. This should be a significant catalyst for a company that already has one of the best operating margins in the sector.
FTNT stock is also one of the <a href="https://www.marketbeat.com/videos/analysts-predict-big-gains-for-these-3-cybersecurity-leaders/" rel="noreferrer noopener" target="_blank">most upgraded stocks</a>. As of March 4, 2025, the Fortinet analyst forecasts on MarketBeat had a consensus price target of $103.72, which is about 3% lower than its current price. However, in the last 30 days, analysts have raised their price targets to levels that would give the stock an upside of around 20%.
Investors are wondering if the AI trade has peaked. The emergence of China&#39;s DeepSeek is weighing on some stocks focused on AI infrastructure. However, cybersecurity is less exposed to tariff risks, which will keep analysts focused on the increasing demand for cybersecurity caused by AI&#39;s growth.
<h2>Texas Roadhouse: This Restaurant Stock Just Flashed a Buy Signal</h2>
Restaurant stocks can be sensitive to tariffs for many reasons, including the cost of ingredients, supply chain snafus, and waning consumer demand.
[content-module:CompanyOverview|NASDAQ:TXRH]
However, this sector can be an example of a stock picker&#39;s market, and&nbsp;<a href="https://www.marketbeat.com/stocks/NASDAQ/TXRH/" rel="noreferrer noopener" target="_blank">Texas Roadhouse Inc. (NASDAQ: </a><a class="ticker" href="https://www.benzinga.com/stock/txrh#NASDAQ">TXRH</a>) is one of the best names to consider as discretionary dollars become tight.
Texas Roadhouse is simply one of the most well-run restaurant chains in the United States. And in the fourth quarter of 2024, it continued to post high single-digit year-over-year (YoY) growth in same-store sales. Plus, the company is still planning to open more restaurants in 2025.
And one of the reasons to buy TXRH stock now can be found in the company&#39;s stock chart. Late in February, the stock hit a low around $169 which formed an almost perfect double-bottom pattern. This can be a bullish signal and sure enough in the seven trading days ending March 4, the stock is up about 10%.
<h2>Lowe&#39;s: A Stable Stock for Long-Term Investors</h2>
Investing in <a href="https://www.marketbeat.com/stocks/sectors/retail-wholesale/" rel="noreferrer noopener" target="_blank">retail stocks</a> has been tricky in the past two years. Consumers have mostly absorbed inflation and rising interest rates. And now tariffs are driving up prices again.
[content-module:CompanyOverview|NYSE:LOW]
<a href="https://www.marketbeat.com/stocks/NYSE/LOW/" rel="noreferrer noopener" target="_blank">Lowe&#39;s Companies Inc. (NYSE: </a><a class="ticker" href="https://www.benzinga.com/stock/low#NYSE">LOW</a>) is exposed to the retail sector via the housing and home improvement market, and it&#39;s been feeling the impact of a weak market on its top and bottom lines.
One of the best reasons to own Lowe&#39;s stock is its dividend. The company is a dividend king that has increased its dividend for 53 consecutive years, and it&#39;s been increasing that dividend at an average annualized growth rate of around 14.8% in the last three years.
LOW stock has been essentially flat over the last twelve months. But if you zoom out on the company&#39;s chart, you can see a bullish pattern where the stock may retreat over 10% but then come back to make new highs. That would be consistent with analyst sentiment, which has a consensus price target of $280.45 for LOW stock.
<h2><a href="https://www.marketbeat.com/newsletter/PDFoffer.aspx?offer=top5&amp;RegistrationCode=SyndicatedArticleLink" style="text-decoration:none;color:var(--dark-blue); font-weight:500;">Where Should You Invest $1,000 Right Now?</a></h2>
Before you make your next trade, you&#39;ll want to hear this.
MarketBeat keeps track of Wall Street&#39;s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the <a href="https://www.marketbeat.com/newsletter/PDFoffer.aspx?offer=top5&amp;RegistrationCode=SyndicatedArticleLink">five stocks</a> that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
<a class="btn btn-featured" href="https://www.marketbeat.com/newsletter/PDFoffer.aspx?offer=top5&amp;RegistrationCode=SyndicatedArticleLink" style="text-decoration:none">See The Five Stocks Here </a>
The article &quot;<a href="https://www.marketbeat.com/stock-ideas/tariffs-wont-stop-these-3-stocks-from-rising/">Tariffs Won&#39;t Stop These 3 Stocks From Rising</a>&quot; first appeared on MarketBeat.

Equities

Markets

FTNT

TXRH

Tariffs Won't Stop These 3 Stocks From Rising

With International Women&#39;s Day just two days away, it&#39;s time to acknowledge the power of women in the business world. Research shows that companies with more women in senior positions tend to be more profitable, socially responsible and better at delivering high-quality customer experiences. According to <a href="https://www.mckinsey.com/featured-insights/diversity-and-inclusion/diversity-matters-even-more-the-case-for-holistic-impact" target="_blank">McKinsey &amp; Company</a>, firms with 30% or more women on their executive teams are 27% more likely to outperform on profitability.
Companies with diverse leadership teams experience greater innovation, better decision-making and higher employee satisfaction. Even their earnings and dividends tend to be more stable over time. Yet, despite these advantages, women still hold a small fraction of top leadership roles. In 2024, only 52 businesses on the Fortune 500 list were run by women, making up just 10.4% of the total. That said, the women who do lead some of the world&#39;s largest companies are making a major impact.
Investing in these companies means backing leaders who prioritize innovation, sustainability and inclusivity. Female CEOs bring diverse perspectives that can drive strong strategies, solid financial results and long-term growth.
This Women&#39;s Day, we highlight five companies with female CEOs who are driving strong business performance and innovation&mdash;Citigroup C, Lumen Technologies LUMN, PG&amp;E PCG, General Motors GM and Expedia Group EXPE.
<h2>Citigroup &mdash; CEO Jane Fraser</h2>
Fraser became Citigroup&#39;s CEO in 2021, making history as the first woman to lead a major U.S. bank. She took charge at a pivotal time when the company was battling complexity. She focused on streamlining operations and boosting competitiveness. Fraser quickly launched a transformation to simplify Citigroup, cutting excess leadership layers and restructuring key divisions, including U.S. personal banking and European operations. Her strategy focused on creating a leaner, more agile institution by eliminating bureaucracy and improving efficiency.
Under her leadership, the bank is becoming more focused and operationally efficient. She also prioritized digital transformation, strengthening Citigroup&#39;s technological capabilities to serve customers better. While challenges remain, Fraser&#39;s efforts have set the stage for long-term growth, ensuring the bank maintains a strong position in the industry.
Citigroup currently sports a Zacks Rank #1 (Strong Buy). The Zacks Consensus Estimate for its 2025 earnings is pegged at $7.53 per share, implying a 26.5% year-over-year increase. You can see&nbsp;<a href="https://www.zacks.com/stocks/buy-list/?adid=ZP_quote_ribbon_1list&amp;icid=quote-detailed_estimates-zp_internal-zacks_premium-top_ribbon-1_rank">the complete list of today&#39;s Zacks #1 Rank stocks here</a>.
<h2>Lumen &mdash; CEO Kate Johnson</h2>
Johnson took over as CEO of Lumen in late 2022, bringing experience in digital transformation from her role as president of Microsoft U.S. Under her direction, Lumen launched its Custom Networks division in 2022, offering tailored A.I. infrastructure solutions.
Last August, Lumen announced that it had secured $5 billion in AI contracts within 100 days, including a key partnership with Microsoft. It was a milestone under Johnson&#39;s leadership. She later steered the company toward an additional $3.5 billion in PCF deals, mainly dark fiber sales, with most cash payments expected within the first four years. At least $3 billion is projected to be received in 2025. These deals strengthened Lumen&#39;s liquidity and helped pay down debt. In 2024, the company generated $1.1 billion in free operating cash flow, a sharp turnaround from a $940 million deficit in 2023.
Johnson is also fostering a culture of adaptability, embracing uncertainties and learning from mistakes. As she puts it, &quot;This was a company that needed to be transformed fundamentally&mdash;and also needed a giant hug. I thought maybe I could lead it in a uniquely feminine way.&quot; Lumen currently sports a Zacks Rank #1.
<h2>PG&amp;E &mdash; CEO Patti Poppe</h2>
When Patti Poppe became CEO of PG&amp;E in 2021, she took on a company recovering from two bankruptcies, battling wildfires and struggling to meet California&#39;s energy needs. She took charge, focusing on rebuilding trust, improving safety and modernizing the grid. Under her leadership, PG&amp;E adopted &quot;lean&quot; programs, training 10,000 workers in cost-cutting measures. In 2023, these efforts saved $68 million in undergrounding electrical lines. In 2024, PG&amp;E saved $650 million across 250 projects through technology upgrades, process improvements and contract renegotiations.
Poppe also secured federal funding to support PG&amp;E&#39;s clean energy transition. The company is using AI to detect wildfires early and collaborating with external experts on solutions. PG&amp;E added 14,000 new customers in 2024 and expects more as data centers and EV charging stations grow, helping to lower costs over time.
PCG currently carries a Zacks Rank #2 (Buy). The Zacks Consensus Estimate for its 2025 earnings is pegged at $1.49/share, suggesting a 10% year-over-year increase.
<h2>General Motors &mdash; CEO Mary Barra</h2>
Barra made history in 2014 as the first female CEO of a major global automaker, taking the helm at GM. Under her leadership, General Motors has aggressively pursued electrification, investing billions in electric vehicles and battery technology. In 2024, GM doubled its U.S. EV market share to 12%. Barra has also prioritized profitability, cost-cutting, and efficiency. GM met its $2 billion net fixed cost reduction target and posted a record $14.9 billion profit in 2024&mdash;up 21% from 2023&mdash;on $187 billion in revenues, a 9% increase.
In China, GM&#39;s restructuring efforts, including rightsizing, new product launches and cost reductions, are beginning to pay off. Barra aims to return its China operations to profitability this year. GM&#39;s strong balance sheet and investor-friendly strategies reinforce its position in the industry.
General Motors currently carries a Zacks Rank #2. The Zacks Consensus Estimate for its 2025 earnings is pegged at $11.46 a share, indicating an 8.11% year-over-year increase.
<h2>Expedia &mdash; CEO Ariane Gorin</h2>
Gorin became Expedia&#39;s CEO in 2024 after spending more than a decade in the company, leading digital transformation and expanding its B2B arm into a multibillion-dollar segment. She also played a key role in the 2021 sale of Egencia to American Express Global Business Travel. When she became the CEO, she aimed to revive Vrbo and Hotels.com while expanding Expedia&#39;s strengths in B2B, advertising and cost discipline.
She remains focused on international growth and on strengthening Expedia&#39;s B2C business. For 2025, Gorin set three priorities: delivering more value to travelers, investing in key growth opportunities and improving efficiency to expand margins. Under her leadership, Expedia is doubling down on AI-driven travel solutions and a revamped loyalty program. With strong travel demand, Gorin&#39;s strategy positions Expedia for its next phase of growth.
EXPE currently carries a Zacks Rank #2. The Zacks Consensus Estimate for its 2025 earnings is pegged at $14.91 a share, implying a 23% year-over-year increase.
&nbsp;
<h2>Only $1 to See All Zacks&#39; Buys and Sells</h2>
We&#39;re not kidding.
Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.
Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like&nbsp;Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.
<a href="https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/6328?adid=SYND_BENZ_ZU_ZU_ANALYSTBLOG_215_IND_03062025_2426499&amp;cid=CS-BENZ-FT-analyst_blog|investment_ideas-2426499" style="font-weight:bold">See Stocks Now &gt;&gt;</a>
&nbsp;
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. <a href="https://www.zacks.com/registration/pfp/?ALERT=RPT_7BST_LP194&amp;ADID=SYND_BENZ_7BEST_ANALYSTBLOG_215_2426499&amp;cid=CS-BENZ-FT-analyst_blog|investment_ideas-2426499" target="_blank">Click to get this free report</a>

&nbsp; 
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=C&amp;ADID=SYND_BENZ_TCK_ANALYSTBLOG_215_2426499_C&amp;cid=CS-BENZ-FT-analyst_blog|investment_ideas-2426499">Citigroup Inc. (NYSE: </a><a class="ticker" href="https://www.benzinga.com/stock/c#NYSE">C</a>): Free Stock Analysis Report 
&nbsp; 
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=PCG&amp;ADID=SYND_BENZ_TCK_ANALYSTBLOG_215_2426499_PCG&amp;cid=CS-BENZ-FT-analyst_blog|investment_ideas-2426499">Pacific Gas &amp; Electric Co. (NYSE: </a><a class="ticker" href="https://www.benzinga.com/stock/pcg#NYSE">PCG</a>): Free Stock Analysis Report 
&nbsp; 
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=EXPE&amp;ADID=SYND_BENZ_TCK_ANALYSTBLOG_215_2426499_EXPE&amp;cid=CS-BENZ-FT-analyst_blog|investment_ideas-2426499">Expedia Group, Inc. (NASDAQ: </a><a class="ticker" href="https://www.benzinga.com/stock/expe#NASDAQ">EXPE</a>): Free Stock Analysis Report 
&nbsp; 
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=GM&amp;ADID=SYND_BENZ_TCK_ANALYSTBLOG_215_2426499_GM&amp;cid=CS-BENZ-FT-analyst_blog|investment_ideas-2426499">General Motors Company (NYSE: </a><a class="ticker" href="https://www.benzinga.com/stock/gm#NYSE">GM</a>): Free Stock Analysis Report 
&nbsp; 
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=LUMN&amp;ADID=SYND_BENZ_TCK_ANALYSTBLOG_215_2426499_LUMN&amp;cid=CS-BENZ-FT-analyst_blog|investment_ideas-2426499">Lumen Technologies, Inc. (LUMN): Free Stock Analysis Report</a>
<a href="https://www.zacks.com/stock/news/2426499/betting-on-female-ceos-5-stocks-to-buy-this-women-s-day?cid=CS-BENZ-FT-analyst_blog|investment_ideas-2426499">This article originally published on Zacks Investment Research (zacks.com).</a>
<a href="https://www.zacks.com/">Zacks Investment Research</a>

EXPE

Betting On Female CEOs: 5 Stocks To Buy This Women's Day

The Gap, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) will release its fourth-quarter financial results, after the <a href="https://www.benzinga.com/quote/gap/earnings">closing bell, on Thursday, March 6</a>.
Analysts expect the company to report quarterly earnings at 38 cents per share, down from 49 cents per share in the year-ago period. Gap projects quarterly revenue of $4.07 billion, compared to $4.3 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Feb. 25, Gap announced a 10% dividend hike to $0.165 per share for the first quarter.
Gap shares fell 0.1% to trade at $19.83 on Thursday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/gap/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>JP Morgan analyst Matthew Boss upgraded the stock from Neutral to Overweight and raised the price target from $28 to $30 on Dec. 2, 2024. This analyst has an accuracy rate of 67%.</li>
<li>UBS analyst Jay Sole maintained a Sell rating and boosted the price target from $14 to $16 on Nov. 22, 2024. This analyst has an accuracy rate of 69%.</li>
<li>Guggenheim analyst Robert Drbul reiterated a Buy rating with a price target of $35 on Nov. 22, 2024. This analyst has an accuracy rate of 60%.</li>
<li>BMO Capital analyst Simeon Siegel maintained a Market Perform rating and raised the price target from $23 to $25 on Nov. 22, 2024. This analyst has an accuracy rate of 75%.</li>
<li>Evercore ISI Group analyst Michael Binetti maintained an Outperform rating and raised the price target from $32 to $33 on Nov. 22, 2024. This analyst has an accuracy rate of 63%.</li>
</ul>
Considering buying GAP stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="423" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06132007/image-23-1024x423.png" alt="" class="wp-image-812780" style="width:589px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06132007/image-23-1024x423.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06132007/image-23-300x124.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06132007/image-23-768x317.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06132007/image-23.png 1471w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/03/44083539/wall-streets-most-accurate-analysts-give-their-take-on-3-defensive-stocks-delivering-high-dividend-yields-3">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Defensive Stocks Delivering High-Dividend Yields</a></li>
</ul>

Earnings

Price Target

Trading Ideas

Top Wall Street Forecasters Revamp Gap Price Expectations Ahead Of Q4 Earnings

On Wednesday, Zymeworks Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYME#NASDAQ">ZYME</a>) released fourth-quarter financial results. The company reported an earnings loss of 31 cents per share, missing the <a target="_blank" href="https://www.benzinga.com/general/biotech" rel="noreferrer noopener">consensus loss of 3 cents</a>.
Sales came at $31.03 million, missing the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $45.2 million</a>.
In its fourth-quarter earnings results, Zymeworks said it is increasing its development <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44151625/zymeworks-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2024-financial-result" rel="noreferrer noopener">efforts on plans for ZW251</a>.
&#8220;Based on our encouraging preclinical results and the unique potential opportunity to help hepatocellular carcinoma patients, we have decided to reprioritize resources for the advancement of ZW251, for which an IND submission is now planned for mid-2025,&#8221; Zymeworks said in a statement.
&#8220;As a result, we have paused preparations for the commencement of Phase 1 studies of ZW220 at this time. However, we believe ZW220 remains a highly differentiated, IND-ready ADC with encouraging preclinical data and strong commercial rationale with partnership potential. We look forward to providing future updates on the development for ZW220,&#8221; the company added.
The company plans to initiate a Phase 1 trial for ZW251 this year.
&#8220;ZW251 provides a new therapeutic modality option targeting GPC3 for hepatocellular carcinoma and represents an emerging opportunity in oncology that has yet to be fully realized,&#8221; said Zymeworks Chief Scientific Officer Paul Moore. &#8220;With a potential best-in-class design and differentiated mechanism, we believe our pipeline presents meaningful opportunities for both strategic partnerships and value creation&#8230;&#8221;
In February, Zymeworks achieved a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43967501/zymeworks-announces-achievement-of-14-million-milestone-from-gsk-collaboration" rel="noreferrer noopener">$14 million cash research</a> milestone associated with a clinical milestone from GSK Plc.
In November 2024, the FDA granted accelerated approval to Zymeworks and Jazz Pharmaceuticals Plc partnered Ziihera (zanidatamab) for adults with previously treated, unresectable, or metastatic HER2-positive (IHC 3+) <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42106981/fda-grants-u-s-approval-of-ziihera-zanidatamab-hrii-for-the-treatment-of-adults-with-previously-tr" rel="noreferrer noopener">biliary tract cancer</a>.
Ziihera was approved under accelerated approval based on a 52% objective response rate (ORR) and a median duration of response of 14.9 months. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Price Action: ZYME stock is down 7.97% at $12.13 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/03/44166646/fda-approves-ars-pharmaceuticals-lower-dose-neffy-nasal-spray-for-emergency-allergy-treatment" target="_blank" rel="noreferrer noopener">FDA Approves ARS Pharmaceuticals&#8217; Lower Dose Neffy Nasal Spray For Emergency Allergy Treatment</a></li>
</ul>
Photo via Shutterstock.

Movers

JAZZ

ZYME

Cancer-Focused Zymeworks' Q4 Earnings Miss Expectations, Reprioritize Resources To Focus On ZW251

Ciena's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) short percent of float has fallen 19.42% since its last report. The company recently reported that it has 3.94 million shares sold short, which is 3.61% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.03 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Ciena Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741284941_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ciena has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Ciena's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Ciena's peer group average for short interest as a percentage of float is 6.00%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

CIEN

Is the Market Bullish or Bearish on Ciena?

Workday's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NYSE">WDAY</a>) short percent of float has fallen 8.03% since its last report. The company recently reported that it has 8.55 million shares sold short, which is 4.01% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.94 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Workday Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741284936_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Workday has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Workday's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Workday's peer group average for short interest as a percentage of float is 2.95%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

WDAY

Looking Into Workday's Recent Short Interest

Oscar Health's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSCR#NYSE">OSCR</a>) short percent of float has risen 13.08% since its last report. The company recently reported that it has 22.11 million shares sold short, which is 10.72% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.71 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Oscar Health Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741284931_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Oscar Health has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Oscar Health's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Oscar Health's peer group average for short interest as a percentage of float is 1.81%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

OSCR

Is the Market Bullish or Bearish on Oscar Health?

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, March 6th:
First United Corporation FUNC: This bank holding company for First United Bank &amp; Trust has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 13.6% over the last 60 days.
<div class="chart_embed">
<h3>First United Corporation Price and Consensus</h3>
<a href="https://www.zacks.com/stock/chart/FUNC/price-consensus-chart?icid=chart-FUNC-price-consensus-chart"><img alt="First United Corporation Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/2d/1741245134.png" style="height:264px; width:568px" title="" /> </a>
<a href="https://www.zacks.com/stock/chart/FUNC/price-consensus-chart?icid=chart-FUNC-price-consensus-chart">First United Corporation price-consensus-chart</a> | <a href="https://www.zacks.com/stock/quote/FUNC?icid=chart-FUNC-price-consensus-chart">First United Corporation Quote</a>
</div>
First United&#39;s shares gained 17.1% over the last six months compared with the S&amp;P 500&#39;s advance of 5.5%. The company possesses a&nbsp;<a href="https://www.zacks.com/style-scores-education/">Momentum Score</a>&nbsp; of B.
<div class="chart_embed">
<h3>First United Corporation Price</h3>
<a href="https://www.zacks.com/stock/chart/FUNC/fundamental/price?icid=chart-FUNC-fundamental/price"><img alt="First United Corporation Price" src="https://staticx-tuner.zacks.com/images/charts/1f/1741245293.png" style="height:250px; width:533px" title="" /> </a>
<a href="https://www.zacks.com/stock/chart/FUNC/fundamental/price?icid=chart-FUNC-fundamental/price">First United Corporation price</a> | <a href="https://www.zacks.com/stock/quote/FUNC?icid=chart-FUNC-fundamental/price">First United Corporation Quote</a>
</div>
Molson Coors Beverage Company TAP: This beer and malt beverages company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 6.4% over the last 60 days.
<div class="chart_embed">
<h3>Molson Coors Beverage Company Price and Consensus</h3>
<a href="https://www.zacks.com/stock/chart/TAP/price-consensus-chart?icid=chart-TAP-price-consensus-chart"><img alt="Molson Coors Beverage Company Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/b0/1741245146.png" style="height:264px; width:568px" title="" /> </a>
<a href="https://www.zacks.com/stock/chart/TAP/price-consensus-chart?icid=chart-TAP-price-consensus-chart">Molson Coors Beverage Company price-consensus-chart</a> | <a href="https://www.zacks.com/stock/quote/TAP?icid=chart-TAP-price-consensus-chart">Molson Coors Beverage Company Quote</a>
</div>
Molson Coors&#39; shares gained 6% over the last six months compared with the S&amp;P 500&#39;s advance of 5.5%. The company possesses a&nbsp;Momentum Score&nbsp;of A.
<div class="chart_embed">
<h3>Molson Coors Beverage Company Price</h3>
<a href="https://www.zacks.com/stock/chart/TAP/fundamental/price?icid=chart-TAP-fundamental/price"><img alt="Molson Coors Beverage Company Price" src="https://staticx-tuner.zacks.com/images/charts/0c/1741245308.png" style="height:250px; width:533px" title="" /> </a>
<a href="https://www.zacks.com/stock/chart/TAP/fundamental/price?icid=chart-TAP-fundamental/price">Molson Coors Beverage Company price</a> | <a href="https://www.zacks.com/stock/quote/TAP?icid=chart-TAP-fundamental/price">Molson Coors Beverage Company Quote</a>
</div>
Camden National Corporation CAC: This bank holding company for Camden National Bank has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 2.2% over the last 60 days.
<div class="chart_embed">
<h3>Camden National Corporation Price and Consensus</h3>
<a href="https://www.zacks.com/stock/chart/CAC/price-consensus-chart?icid=chart-CAC-price-consensus-chart"><img alt="Camden National Corporation Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/53/1741245160.png" style="height:264px; width:568px" title="" /> </a>
<a href="https://www.zacks.com/stock/chart/CAC/price-consensus-chart?icid=chart-CAC-price-consensus-chart">Camden National Corporation price-consensus-chart</a> | <a href="https://www.zacks.com/stock/quote/CAC?icid=chart-CAC-price-consensus-chart">Camden National Corporation Quote</a>
</div>
Camden National&#39;s shares gained 11.2% over the last six months compared with the S&amp;P 500&#39;s advance of 5.5%. The company possesses a&nbsp;Momentum Score&nbsp;of B.
<div class="chart_embed">
<h3>Camden National Corporation Price</h3>
<a href="https://www.zacks.com/stock/chart/CAC/fundamental/price?icid=chart-CAC-fundamental/price"><img alt="Camden National Corporation Price" src="https://staticx-tuner.zacks.com/images/charts/d0/1741245327.png" style="height:250px; width:533px" title="" /> </a>
<a href="https://www.zacks.com/stock/chart/CAC/fundamental/price?icid=chart-CAC-fundamental/price">Camden National Corporation price</a> | <a href="https://www.zacks.com/stock/quote/CAC?icid=chart-CAC-fundamental/price">Camden National Corporation Quote</a>
</div>
&nbsp;
See the&nbsp;<a href="https://www.zacks.com/stocks/buy-list/?ADID=zp_1link&amp;ICID=zpi%20_1link">full list of top ranked stocks here</a>
&nbsp;
Learn more about the&nbsp;<a href="https://www.zacks.com/education/stock-scorecard/momentum-trading">Momentum score and how it is calculated here</a>.
&nbsp;
<h2>Only $1 to See All Zacks&#39; Buys and Sells</h2>
We&#39;re not kidding.
Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.
Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like&nbsp;Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.
<a href="https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/6328?adid=SYND_BENZ_ZU_ZU_ZACKS1RANKADDITIONS_267_03062025_2426354&amp;cid=CS-BENZ-FT-zacks_1_rank_additions|momentum_additions-2426354" style="font-weight:bold">See Stocks Now &gt;&gt;</a>
&nbsp;
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. <a href="https://www.zacks.com/registration/pfp/?ALERT=RPT_7BST_LP194&amp;ADID=SYND_BENZ_7BEST_ZACKS1RANKADDITIONS_267_2426354&amp;cid=CS-BENZ-FT-zacks_1_rank_additions|momentum_additions-2426354" target="_blank">Click to get this free report</a>

&nbsp; 
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=TAP&amp;ADID=SYND_BENZ_TCK_ZACKS1RANKADDITIONS_267_2426354_TAP&amp;cid=CS-BENZ-FT-zacks_1_rank_additions|momentum_additions-2426354">Molson Coors Beverage Company (NYSE: </a><a class="ticker" href="https://www.benzinga.com/stock/tap#NYSE">TAP</a>): Free Stock Analysis Report 
&nbsp; 
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=CAC&amp;ADID=SYND_BENZ_TCK_ZACKS1RANKADDITIONS_267_2426354_CAC&amp;cid=CS-BENZ-FT-zacks_1_rank_additions|momentum_additions-2426354">Camden National Corporation (NASDAQ: </a><a class="ticker" href="https://www.benzinga.com/stock/cac#NASDAQ">CAC</a>): Free Stock Analysis Report 
&nbsp; 
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=FUNC&amp;ADID=SYND_BENZ_TCK_ZACKS1RANKADDITIONS_267_2426354_FUNC&amp;cid=CS-BENZ-FT-zacks_1_rank_additions|momentum_additions-2426354">First United Corporation (NASDAQ: </a><a class="ticker" href="https://www.benzinga.com/stock/func#NASDAQ">FUNC</a>): Free Stock Analysis Report
<a href="https://www.zacks.com/commentary/2426354/best-momentum-stocks-to-buy-for-march-6th?cid=CS-BENZ-FT-zacks_1_rank_additions|momentum_additions-2426354">This article originally published on Zacks Investment Research (zacks.com).</a>
<a href="https://www.zacks.com/">Zacks Investment Research</a>

FUNC

Best Momentum Stocks To Buy For March 6th

Gorilla Technology Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRRR#NASDAQ">GRRR</a>) shares are tanking Thursday after The Bear Cave released a short report on the company. Here&#8217;s what investors <a href="https://www.benzinga.com/wiim/25/03/44170175/gorilla-technology-group-shares-are-trading-lower-following-a-short-report-from-the-bear-cave">need to know</a>.
What To Know: Short seller The Bear Cave released a bearish report on Gorilla Technology Thursday morning in response to the stock&#8217;s approximately 1,200% rise over the past six months, driven by retail investor enthusiasm surrounding recent partnership announcements.
&#8220;The Bear Cave believes recent retail investor enthusiasm for the company may be premature,&#8221; the short seller said.
The Bear Cave pointed out several red flags at Gorilla Technology including the company&#8217;s aggressive pivot to AI technology, its revenue streams, unconventional partnerships and controls over financial reporting.
Benzinga has reached out to Gorilla Technology Group for comment on The Bear Cave report.
The Bear Cave noted that Gorilla Technology was founded in 2001 as a video analytics company. The company recently pivoted its focus to AI technology under current chairman and CEO Jay Chandan, who also led the special purpose acquisition company <a href="https://www.benzinga.com/topic/spacs">(SPAC)</a> that brought Gorilla public in 2022. 
Check This Out: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/03/44171776/victorias-secret-turnaround-in-progress-but-challenges-remain-analyst-lowers-forecast">Victoria&#8217;s Secret Turnaround In Progress But Challenges Remain: Analyst Lowers Forecast</a>
The short seller highlighted a myriad of trendy technologies that Gorilla says it focuses on including smart cities, blockchain technology, <a href="http://benzinga.com/topic/ai">AI</a> and the Internet of Things. The Bear Cave also noted that in the company&#8217;s most recent annual report, it disclosed that approximately 94% of revenue came from two customers: the Government of Egypt and the Criminal Investigation Bureau of Taiwan.
Despite the underwhelming financials, retail investors have bid up the stock on the back of a series of optimistic announcements including a deal with ONE Amazon to power the &#8220;Internet of Forests&#8221; in the Amazon Rainforest.
The Bear Cave also raised questions around the company&#8217;s financial reporting, noting that the company&#8217;s former CFO resigned with &#8220;no apparent notice&#8221; in September 2024 and was replaced by a CFO who appears to have limited experience.
&#8220;Even for the most trusting investor, some of Gorilla's statements seem to be a stretch,&#8221; the short seller said.
Gorilla Technology&#8217;s longtime auditor was also dismissed last year after the company disclosed material weaknesses in its internal control over financial reporting. The company engaged an auditor from Marcum Asia who has served as an audit engagement partner for several other companies, all of which have performed poorly in public markets, according to The Bear Cave. 
GRRR Price Action: <a href="http://benzinga.com/quote/grrr">Gorilla Technology shares</a> were down 22.5% at $32.24 at the time of publication Thursday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44168987/oil-prices-hit-multi-year-lows">Oil Prices Hit Multi-Year Lows As OPEC+ Production, Tariffs Weigh On Market</a></li>
</ul>
This illustration was generated using artificial intelligence via Midjourney.

GRRR

Short Seller Targets Gorilla Technology Group Stock, Investors Take Profits

Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) will release its first-quarter financial results, after the <a href="https://www.benzinga.com/quote/AVGO/earnings">closing bell, on Thursday, March 6</a>.
Analysts expect the Palo Alto, California-based company to report quarterly earnings at $1.51 per share, up from $1.1 per share in the year-ago period. Broadcom projects quarterly revenue of $14.59 billion, compared to $11.96 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
The company missed analyst estimates for revenue in the fourth quarter, while it has beaten estimates in eight of the last 10 quarters.
Broadcom shares fell 5.7% to trade at $180.67 on Thursday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/avgo/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Morgan Stanley analyst Joseph Moore maintained an Overweight rating and cut the price target from $265 to $246 on Jan. 28, 2025. This analyst has an accuracy rate of 69%.</li>
<li>Mizuho analyst Vijay Rakesh maintained an Outperform rating and boosted the price target from $245 to $260 on Jan. 10, 2025. This analyst has an accuracy rate of 74%.</li>
<li>JP Morgan analyst Harlan Sur maintained an Overweight rating and increased the price target from $210 to $250 on Dec. 13, 2024. This analyst has an accuracy rate of 77%.</li>
<li>TD Cowen analyst Matthew Ramsay maintained a Buy rating and raised the price target from $210 to $240 on Dec. 13, 2024. This analyst has an accuracy rate of 71%.</li>
<li>Benchmark analyst Cody Acree reiterated a Buy rating and raised the price target from $210 to $255 on Dec. 13, 2024. This analyst has an accuracy rate of 65%.</li>
</ul>
Considering buying AVGO stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="582" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06131058/image-22-1024x582.png" alt="" class="wp-image-812759" style="width:566px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06131058/image-22-1024x582.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06131058/image-22-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06131058/image-22-768x437.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06131058/image-22.png 1103w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/03/44083539/wall-streets-most-accurate-analysts-give-their-take-on-3-defensive-stocks-delivering-high-dividend-yields-3">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Defensive Stocks Delivering High-Dividend Yields</a></li>
</ul>

AVGO

Broadcom Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

RBC Capital Markets analyst Nik Modi reiterated the Sector Perform rating on Campbell&#8217;s Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NASDAQ">CPB</a>), lowering the price forecast to $44 from $51.
Yesterday, the company reported second-quarter sales growth of 9% to $2.685 billion, <a target="_blank" href="https://www.benzinga.com/25/03/44140506/campbells-stocks-fall-on-q2-sales-miss-and-gloomy-outlook" rel="noreferrer noopener">missing the analyst&nbsp;consensus estimate of $2.74 billion.</a>
For FY25, Campbell&nbsp;sees net sales growth of 6% to 8% (prior view: 9%&nbsp;to&nbsp;11%). Adjusted EBIT growth&nbsp;of 3% to 5% (previous view: 9%&nbsp;to&nbsp;11%).
Modi suggests that while Campbell&#8217;s challenging results and full-year guidance cut were anticipated, the company made a wise decision to address these issues upfront, allowing them to focus on performance improvements despite ongoing macro and consumer challenges.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/03/44171189/whats-going-on-with-exxon-mobil-xom-shares" rel="noreferrer noopener">What&#8217;s Going On With Exxon Mobil (XOM) Shares?</a>
Additionally, Campbell&#8217;s Company is considered undervalued compared to its peers and historical performance, though the analyst stresses that further efforts are needed before the stock can see positive movement.
The analyst states in response to F2Q results, estimates were adjusted for FY25 net sales growth to +6.7% (prior view: +9.2%), organic sales growth to -1.2% (prior view: +0.4%), EBIT growth to +9.2% (prior view: from +3.2%) and EPS to $2.99 (prior view: $3.17).
Per the analyst, lowering the full-year guidance was the right move, but due to the fluid environment, Modi remains cautious and slightly below the midpoint of the company&#8217;s top-line guidance, anticipating consumer sentiment could &#8220;soften&#8221; further.
CPB Price Action: Campbell&#8217;s Co. shares are trading higher by 0.61% to $39.40 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/03/44171377/retailers-warn-of-price-increases-due-to-trump-tariffs-as-consumer-health-concerns-persist" target="_blank" rel="noreferrer noopener">Retailers Warn Of Price Increases Due To Trump Tariffs As Consumer Health Concerns Persist</a></li>
</ul>
Photo: JHVEPhoto via Shutterstock

Reiteration

Campbell's Faces Slower Growth: Analyst Cuts Price Forecast As Consumer Sentiment Could Weaken Further

HC Wainwright has initiated coverage on ImmunityBio, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>). The company's lead asset is Anktiva (nogapendekin alfa inbakicept-pmln) solution for intravesical use, approved by the Food and Drug Administration indicated with Bacillus Calmette-Guérin (BCG) for adult patients with BCG-unresponsive bladder carcinoma in situ (CIS) with or <a href="https://www.benzinga.com/general/biotech">without papillary tumors</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43038889/immunitybio-stock-trading-higher-on-updates-from-bladder-cancer-trials-details" rel="noreferrer noopener">ImmunityBio Stock Trading Higher On Updates From Bladder Cancer Trials: Details</a>
HC Wainwright analyst Andres Y. Maldonado writes that Anktiva will follow a different market path than the two latest FDA-approved treatments for high-risk bladder cancer—Merck &amp; Co Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Keytruda and Ferring Pharmaceutical's Adstiladrin—both of which have faced hurdles after launch.
Keytruda's adoption has been slow because urologists are hesitant to refer patients to oncologists and worry about its side effects. Adstiladrin, on the other hand, has struggled with supply issues, though Ferring says availability has recently improved.
HC Wainwright projects 2025 Anktiva revenue of $137.4 million, growing to $4.3 billion by 2034. The analyst has initiated with a Buy rating <a href="https://www.benzinga.com/quote/IBRX/analyst-ratings" target="_blank" rel="noreferrer noopener">and an $8 price target</a>.
In the fourth quarter, ImmunityBio reported <a href="https://www.benzinga.com/pressreleases/25/03/b44073991/immunitybio-reports-sales-momentum-unit-growth-since-permanent-j-code-issuance-j9028-in-january-20">product revenue of $7.21 million</a> and $14.2 million in the fiscal year 2024. The increase was driven by sales of ANKTIVA after FDA <a href="https://www.benzinga.com/general/biotech/24/04/38380405/fda-approves-immunitybios-bladder-cancer-drug-stock-rallies" target="_blank" rel="noreferrer noopener">approval in April 2024</a>.
Recently, the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for Anktiva and CAR-NK (PD-L1 t-haNK) for the reversal of lymphopenia in patients receiving standard-of-care chemotherapy/radiotherapy and in multiply relapsed locally advanced or <a target="_blank" href="http://lymphopenia in patients receiving standard-of-care chemotherapy/radiotherapy and in multiply relapsed locally advanced or metastatic pancreatic cancer." rel="noreferrer noopener">metastatic pancreatic cancer</a>.
While many are watching the competition between CG Oncology Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGON#NASDAQ">CGON</a>) cretostimogene and Johnson &amp; Johnson's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) TAR-200 in the NMIBC market, Anktiva stands out with a first-mover advantage in a market potentially worth over $5 billion, the analyst says.
&#8220;Ultimately, we believe ANKTIVA's profile coupled with ease of administration will weigh more heavily in treatment decisions than comparisons of complete response (CR) rates at various time points to unapproved products,&#8221; the analyst writes.
Price Action: IBRX stock is down 2.47% at $2.98 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/03/44169989/federal-judge-halts-national-institutes-of-healths-grant-policy-overhaul-citing-legal-violations" target="_blank" rel="noreferrer noopener">Federal Judge Halts National Institutes of Health&#8217;s Grant Policy Overhaul Citing Legal Violations</a></li>
</ul>
Photo: Shutterstock

Initiation

CGON

IBRX

ImmunityBio Analyst Predicts Strong 2025 For New Bladder Cancer Drug

Macro Economic Events

Global

Economics

President Trump's Special Envoy Witkoff Says In Discussions To Coordinate Meeting With Ukraine In Saudi Arabia; Trying To Get A Framework For Peace Agreement And Initial Ceasefire For Ukraine

STLA

TSLA

Mexico President Claudia Sheinbaum Says We Want A Good Part Of Auto Makers' Production In Mexico To Be For Local Market

B of A Securities analyst Allen Lutz reiterates Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) with a Underperform and maintains $21 price target.

Hims & Hers Health, Inc. Class A Common Stock

HIMS

B of A Securities Reiterates Underperform on Hims & Hers Health, Maintains $21 Price Target

Alliance Global Partners analyst James Molloy reiterates IGC Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IGC#AMEX">IGC</a>) with a Buy and maintains $3.5 price target.

Alliance Global Partners Reiterates Buy on IGC Pharma, Maintains $3.5 Price Target

American Express (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) today announced that it has entered into an agreement to acquire <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fgetcenter.com&amp;esheet=54220394&amp;newsitemid=20250306154813&amp;lan=en-US&amp;anchor=Center&amp;index=1&amp;md5=31f976a9bf2007ec4f13a62801dc8cb7">Center</a>,a software company modernizing expense management.
This press release features multimedia. View the full release here: <a href="https://www.businesswire.com/news/home/20250306154813/en/">https://www.businesswire.com/news/home/20250306154813/en/</a>
Center's software, together with American Express' corporate and small business cards, will aim to create a seamless expense management platform that delivers more value across the commercial card payments process – from choice in premium card offerings and rewards to automated accounting and reconciliation.

American Express To Acquire Center, A Software Company Modernizing Expense Management; No Financial Terms Disclosed

Across the recent three months, 20 analysts have shared their insights on Uber Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">8</td>
<td align="right">11</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">4</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $89.85, along with a high estimate of $115.00 and a low estimate of $80.00. Observing a downward trend, the current average is 1.75% lower than the prior average price target of $91.45. 
<img src="https://www.benzinga.com/files/images/story/2025/1741284100_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Uber Technologies is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Youssef Squali</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$92.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Thomas Champion</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$87.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$82.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Tom White</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$80.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Mark Mahaney</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$87.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Ronald Josey</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$92.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Thomas Champion</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Lloyd Walmsley</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$107.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Thomas Champion</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$82.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Shweta Khajuria</td>
<td>Wolfe Research</td>
<td>Raises</td>
<td>Outperform</td>
<td>$92.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Eric Sheridan</td>
<td>Goldman Sachs</td>
<td>Maintains</td>
<td>Buy</td>
<td>$96.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Andrew Boone</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$95.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Uber Technologies. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Uber Technologies compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Uber Technologies's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Uber Technologies's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/UBER/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Uber Technologies analyst ratings.</a>
<h2>Unveiling the Story Behind Uber Technologies</h2>
Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food couriers, and shippers with carriers. The firm's on-demand technology platform is currently utilized by traditional cars as well as autonomous vehicles, but could eventually be used for additional products and services, such as delivery via drones or electronic vehicle take-off and landing (eVTOL) technology. Uber operates in over 70 countries, with over 171 million users who order rides or food at least once a month.
<h3>Uber Technologies: A Financial Overview</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Over the 3 months period, Uber Technologies showcased positive performance, achieving a revenue growth rate of 20.36% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 57.55%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Uber Technologies's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 37.88% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Uber Technologies's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 14.0% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Uber Technologies's debt-to-equity ratio is below the industry average. With a ratio of 0.52, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

UBER

20 Analysts Assess Uber Technologies: What You Need To Know

In the preceding three months, 4 analysts have released ratings for Riskified (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSKD#NYSE">RSKD</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $6.12, a high estimate of $7.00, and a low estimate of $4.50. This upward trend is evident, with the current average reflecting a 11.27% increase from the previous average price target of $5.50.
<img src="https://www.benzinga.com/files/images/story/2025/1741284093_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Riskified. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Will Nance</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Sell</td>
<td>$4.50</td>
<td>$4.00</td>
</tr>
<tr>
<td>Clarke Jeffries</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$7.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$7.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Clarke Jeffries</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$6.00</td>
<td>$7.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Riskified. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Riskified compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
For valuable insights into Riskified's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/RSKD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Riskified analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Riskified: A Closer Look</h2>
Riskified Ltd has built a next-generation eCommerce risk management platform that allows online merchants to create trusted relationships with their consumers. It generates revenue by granting merchants access to its eCommerce risk management platform and reviewing and approving eCommerce transactions for legitimacy. Its merchants include some of the ecommerce brands including Wayfair, Lastminute.com, SHEIN, and Macy's. Its merchants operate in a variety of verticals, including Payments, Money Transfer &amp; Crypto, Tickets &amp; Travel, Electronics, Home, Fashion &amp; Luxury Goods, General Retail and Food. The company derived maximum revenue from Israel.
<h3>Key Indicators: Riskified's Financial Health</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Riskified displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 9.71%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -12.3%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Riskified's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -2.34%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Riskified's ROA excels beyond industry benchmarks, reaching -1.88%. This signifies efficient management of assets and strong financial health.
Debt Management: Riskified's debt-to-equity ratio is below the industry average at 0.07, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RSKD

Beyond The Numbers: 4 Analysts Discuss Riskified Stock

Press Releases

BioNexus Gene Lab Corp. Agrees to Invest RM 1.2 million in Ascension Innovation (AISB) to Advance Digital Health Innovation through AI adoption in Healthcare

Financing

BioNexus Gene Lab Corp. Completes Strategic RM 1 Million Investment in Ascension Innovation Sdn Bhd

BioNexus Gene Lab Corp. Announces Successful Securities Commission of Malaysia (MyCIF) Co-Investment in Ascension Innovation Sdn Bhd

BioNexus Gene Lab Corp Announces New Business Developments for Subsidiary Chemrex with Investment in High-Quality Color Paste Production

BioNexus Gene Lab Corp. Signs Strategic Partnership MOU with Shenzhen Rongguang Group to Advance Cancer Screening, Precision Medicine, and Preventative Healthcare Solutions

BioNexus Gene Lab Corp. Signs Strategic Outsourcing Agreement with VITARRAY Global Pte. Ltd.

BioNexus Gene Lab Corporation announces entry into Biogas Sector via Teaming Agreement with Protech Builders Sdn. Bhd.

BioNexus Gene Lab Corp. Announces Board Approval of Ethereum Treasury Strategy and Release of Strategic Whitepaper

BGLC

Alta Equipment Group Inc. Class A Common Stock

Alta Equipment Group

Euro Tech Holdings Company Limited - Ordinary Shares

Euro Tech Hldgs

EVI Industries

FGI Industries

Hudson Technologies

iPower

Karat Packaging

Lavoro

Multi Ways Holdings Limited Ordinary Shares

Multi Ways Holdings

Simpple

Titan Machinery

ZKH Group Limited American Depositary Shares, each representing thirty-five (35) Class A Ordinary Shares

Comments

BioNexus Gene Lab

ニュース

最新ニュース BioNexus Gene Lab (NASDAQ:BGLC) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル